You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Takeda and Janssen are teaming up with wearable device maker ActiGraph to validate a digital measure that quantifies the disruptive nighttime scratching that impacts people with skin conditions like psoriasis and atopic dermatitis. The hope is that a measure of so-called nocturnal scratch might one day be used as an endpoint in clinical trials for new drugs.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect